Victory Capital Management Inc Tyme Technologies, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 01, 2022	BUY	$0.23 - $0.35 $29 - $45	130 Added 0.78%	16,693 $5,000
Q1 2022 May 04, 2022	SELL	$0.28 - $0.68 $62 - $150	-222 Reduced 1.32%	16,563 $5,000
Q4 2021 Feb 07, 2022	SELL	$0.6 - $1.04 $157 - $273	-263 Reduced 1.54%	16,785 $10,000
Q3 2021 Nov 02, 2021	SELL	$0.99 - $1.38 $934 - $1,302	-944 Reduced 5.25%	17,048 $18,000
Q2 2021 Aug 03, 2021	SELL	$1.14 - $1.87 $637 - $1,045	-559 Reduced 3.01%	17,992 $23,000
Q1 2021 May 04, 2021	BUY	$1.34 - $3.53 $8,786 - $23,146	6,557 Added 54.67%	18,551 $33,000
Q4 2020 Feb 01, 2021	BUY	$0.87 - $1.26 $10,434 - $15,112	11,994 New	11,994 $15,000
Q2 2020 Aug 07, 2020	SELL	$0.97 - $1.7 $8,874 - $15,553	-9,149 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$0.9 - $1.95 $23 - $50	26 Added 0.28%	9,149 $10,000
Q4 2019 Feb 04, 2020	BUY	$1.0 - $1.49 $1,350 - $2,011	1,350 Added 17.37%	9,123 $13,000
Q3 2019 Nov 12, 2019	BUY	$0.97 - $1.77 $7,539 - $13,758	7,773 New	7,773 $9,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.